The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $15.84 in the prior trading day, Travere Therapeutics Inc (NASDAQ: TVTX) closed at $15.34, down -3.16%. In other words, the price has decreased by -$3.16 from its previous closing price. On the day, 1.77 million shares were traded.
Ratios:
Our goal is to gain a better understanding of TVTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.03 and its Current Ratio is at 2.05. In the meantime, Its Debt-to-Equity ratio is 12.20 whereas as Long-Term Debt/Eq ratio is at 9.94.
On October 21, 2024, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight and also upped its target price recommendation from $9 to $27.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 05 ’25 when Cline Christopher R. sold 1,784 shares for $21.05 per share. The transaction valued at 37,553 led to the insider holds 93,126 shares of the business.
Dube Eric M sold 18,924 shares of TVTX for $398,350 on May 05 ’25. The CHIEF EXECUTIVE OFFICER now owns 419,173 shares after completing the transaction at $21.05 per share. On May 05 ’25, another insider, Heerma Peter, who serves as the CHIEF COMMERCIAL OFFICER of the company, sold 1,771 shares for $21.05 each. As a result, the insider received 37,280 and left with 128,215 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.98 while its Price-to-Book (P/B) ratio in mrq is 41.50.
Stock Price History:
Over the past 52 weeks, TVTX has reached a high of $25.29, while it has fallen to a 52-week low of $6.14. The 50-Day Moving Average of the stock is -15.63%, while the 200-Day Moving Average is calculated to be -11.08%.
Shares Statistics:
A total of 88.79M shares are outstanding, with a floating share count of 87.44M. Insiders hold about 1.54% of the company’s shares, while institutions hold 112.74% stake in the company.
Earnings Estimates
The current rating of Travere Therapeutics Inc (TVTX) is the result of assessments by 8.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.06, with high estimates of $0.08 and low estimates of -$0.17.
Analysts are recommending an EPS of between $0.29 and -$0.82 for the fiscal current year, implying an average EPS of -$0.24. EPS for the following year is $1.33, with 10.0 analysts recommending between $2.38 and $0.22.
Revenue Estimates
12 analysts predict $101.49M in revenue for the current quarter. It ranges from a high estimate of $114.4M to a low estimate of $77.76M. As of the current estimate, Travere Therapeutics Inc’s year-ago sales were $54.12MFor the next quarter, 12 analysts are estimating revenue of $100.17M. There is a high estimate of $112.26M for the next quarter, whereas the lowest estimate is $90.54M.
A total of 14 analysts have provided revenue estimates for TVTX’s current fiscal year. The highest revenue estimate was $444.38M, while the lowest revenue estimate was $333.83M, resulting in an average revenue estimate of $397.34M. In the same quarter a year ago, actual revenue was $233.18MBased on 14 analysts’ estimates, the company’s revenue will be $568M in the next fiscal year. The high estimate is $795.9M and the low estimate is $450.21M.
